Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Int J Cancer ; 146(7): 1950-1962, 2020 04 01.
Artículo en Inglés | MEDLINE | ID: mdl-31376303

RESUMEN

Heme oxygenase 1 (HO-1) plays a pivotal role in preventing cell damage. Indeed, through the antioxidant, antiapoptotic and anti-inflammatory properties of its metabolic products, it favors cell adaptation against different stressors. However, HO-1 induction has also been related to the gain of resistance to therapy in different types of cancers and its involvement in cancer immune-escape has been hypothesized. We have investigated the role of HO-1 expression in Vemurafenib-treated BRAFV600 melanoma cells in modulating their susceptibility to NK cell-mediated recognition. Different cell lines, isolated in house from melanoma patients, have been exposed to 1-10 µM PLX4032, which efficiently reduced ERK phosphorylation. In three lines, Vemurafenib was able to induce only a limited decrease in cell viability, while HO-1 expression was upregulated. HO-1 silencing/inhibition was able to induce a further significant reduction of Vemurafenib-treated melanoma viability. Moreover, while NK cell degranulation and killing activity were decreased upon interaction with melanoma exposed to Vemurafenib, HO-1 silencing was able to completely restore NK cell ability to degranulate and kill. Furthermore, melanoma cell treatment with Vemurafenib downregulated the expression of ligands of NKp30 and NKG2D activating receptors, and HO-1 silencing/inhibition was able to restore their expression. Our results indicate that HO-1 downregulation can both improve the efficacy of Vemurafenib on melanoma cells and favor melanoma susceptibility to NK cell-mediated recognition and killing.


Asunto(s)
Regulación Neoplásica de la Expresión Génica/efectos de los fármacos , Hemo-Oxigenasa 1/genética , Células Asesinas Naturales/efectos de los fármacos , Células Asesinas Naturales/metabolismo , Mutación , Proteínas Proto-Oncogénicas B-raf/genética , Vemurafenib/farmacología , Biomarcadores , Línea Celular Tumoral , Citotoxicidad Inmunológica , Silenciador del Gen , Hemo-Oxigenasa 1/metabolismo , Humanos , Inmunofenotipificación , Células Asesinas Naturales/inmunología , Receptores de Células Asesinas Naturales/metabolismo
2.
Front Oncol ; 8: 199, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-29951371

RESUMEN

Heme oxygenase 1 (HO-1) is crucially involved in cell adaptation to oxidative stress and has been demonstrated to play an important role in cancer progression and resistance to therapies. We recently highlighted that undifferentiated neuroblastoma (NB) cells are prone to counteract oxidative stress through the induction of HO-1. Conversely, differentiated NB cells were more sensitive to oxidative stress since HO-1 was scarcely upregulated. In this work, we investigated the role played by miR-494, which has been proved to be involved in cancer biology and in the modulation of oxidative stress, in the upregulation of HO-1. We showed that NB differentiation downregulates miR-494 level. In addition, endogenous miR-494 inhibition in undifferentiated cells impairs HO-1 induction in response to exposure to 500 µM H2O2, reducing the number of viable cells. The analysis of Bach1 expression did not reveal any significant modifications in any experimental conditions tested, proving that the impairment of HO-1 induction observed in cells treated with miR-494 inhibitor and exposed to H2O2 is independent from Bach1. Our results underline the role played by miR-494 in favoring HO-1 induction and cell adaptation to oxidative stress and contribute to the discovery of new potential pharmacological targets to improve anticancer therapies.

3.
Neurobiol Aging ; 35(6): 1301-8, 2014 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-24484607

RESUMEN

The aggregation of amyloid-ß (Aß) peptides plays a crucial role in the onset and progression of Alzheimer's disease. Monomeric form of Aß, indeed, could exert a physiological role. Considering the anti-oligomerization property of all-trans retinoic acid (ATRA), the involvement of monomeric Aß1-42 in ATRA-induced neuronal differentiation has been investigated. Four-day ATRA treatment increases ß-secretase 1 (BACE1) level, Aß1-42 production, and receptor for advanced glycation end-products (RAGE) expression. RAGE is a well-recognized receptor for Aß, and the block of both RAGE and Aß1-42 with specific antibodies strongly impairs neurite formation in ATRA-treated cells. The involvement of Aß1-42 and RAGE in ATRA-induced morphologic changes has been confirmed treating undifferentiated cells with different molecular assemblies of peptide: 1 µM monomeric, but not oligomeric, Aß1-42 increases RAGE expression and favors neurite elongation. The block of RAGE completely prevents this effect. Furthermore, our data underline the involvement of the RAGE-dependent adhesion molecule amphoterin-induced gene and open reading frame-1 as downstream effector of both ATRA and Aß1-42. In conclusion, our findings identify a novel physiological role for monomeric Aß1-42 and RAGE in neuronal differentiation.


Asunto(s)
Enfermedad de Alzheimer/genética , Enfermedad de Alzheimer/patología , Péptidos beta-Amiloides/química , Péptidos beta-Amiloides/fisiología , Diferenciación Celular/genética , Neuronas/citología , Fragmentos de Péptidos/química , Fragmentos de Péptidos/fisiología , Receptores Inmunológicos/fisiología , Secretasas de la Proteína Precursora del Amiloide/metabolismo , Secretasas de la Proteína Precursora del Amiloide/fisiología , Péptidos beta-Amiloides/inmunología , Péptidos beta-Amiloides/metabolismo , Anticuerpos/farmacología , Ácido Aspártico Endopeptidasas/metabolismo , Ácido Aspártico Endopeptidasas/fisiología , Diferenciación Celular/efectos de los fármacos , Progresión de la Enfermedad , Humanos , Glicoproteínas de Membrana/genética , Glicoproteínas de Membrana/fisiología , Proteínas del Tejido Nervioso/genética , Proteínas del Tejido Nervioso/fisiología , Neuritas/fisiología , Neuronas/fisiología , Sistemas de Lectura Abierta , Fragmentos de Péptidos/inmunología , Fragmentos de Péptidos/metabolismo , Polimerizacion/efectos de los fármacos , Receptor para Productos Finales de Glicación Avanzada , Receptores Inmunológicos/inmunología , Receptores Inmunológicos/metabolismo , Tretinoina/farmacología , Células Tumorales Cultivadas , Regulación hacia Arriba/efectos de los fármacos , Regulación hacia Arriba/fisiología
4.
Int J Mol Sci ; 14(6): 10694-709, 2013 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-23702842

RESUMEN

The aim of this work was to evaluate the ability of oxidative and glycative stressors to modify properties of human serum albumin (HSA) by analyzing markers of glycation (pentosidine) and oxidation (advanced oxidative protein products (AOPPs)) and assessing fluorescence and circular dichroism. HSA was incubated for up to 21 days with ribose, ascorbic acid (AA) and diethylenetriamine pentacetate (DTPA) in various combinations in order to evaluate influences of these substances on the structure of HSA. Ribose was included as a strong glycative molecule, AA as a modulator of oxidative stress, and DTPA as an inhibitor of metal-catalyzed oxidation. Ribose induced a significant increase in pentosidine levels. AA and DTPA prevented the accumulation of pentosidine, especially at later time points. Ribose induced a mild increase in AOPP formation, while AA was a strong inducer of AOPP formation. Ribose, in combination with AA, further increased the formation of AOPP. DTPA prevented the AA-induced generation of AOPP. Ribose was also a potent inducer of fluorescence at 335nm ex/385nm em, which is typical of pentosidine. AA and DTPA prevented this fluorescence. Circular dichroism showed complex results, in which AA and DTPA were strong modifiers of the percentages of the alpha-helical structure of HSA, while ribose affected the structure of HSA only at later time points.


Asunto(s)
Estrés Oxidativo , Albúmina Sérica/química , Albúmina Sérica/metabolismo , Acetatos/farmacología , Arginina/análogos & derivados , Arginina/farmacología , Ácido Ascórbico/farmacología , Dicroismo Circular , Fluorescencia , Glicosilación/efectos de los fármacos , Humanos , Lisina/análogos & derivados , Lisina/farmacología , Oxidación-Reducción/efectos de los fármacos , Estrés Oxidativo/efectos de los fármacos , Estructura Secundaria de Proteína
5.
Neurosci Lett ; 416(3): 261-5, 2007 Apr 18.
Artículo en Inglés | MEDLINE | ID: mdl-17317001

RESUMEN

Advanced glycation end product (AGE) accumulation in brain is believed to contribute to neuronal death in several neurodegenerative diseases. Neurons exposed to AGEs undergo oxidative stress, but the molecular mechanisms able to induce ROS generation and cell death are not yet clear. In this work, we exposed SH-SY5Y neuroblastoma cells to glycated albumin, as a model of AGE-modified protein, and we observed that cells differentiated by retinoic acid died after AGE exposure, through anion superoxide and peroxide generation, while undifferentiated cells resulted resistant. Retinoic acid induced marked increase in p47phox expression and in catalytic activity of PKC delta: the upregulation of a pathway involving NADPH oxidase and PKC delta is likely to be responsible for neuronal susceptibility to AGE. This hypothesis is confirmed by the fact that pre-treatments of differentiated cells with DPI, an inhibitor of NADPH oxidase, or with rottlerin, an inhibitor of PKC delta, were able to prevent AGE-induced neuronal death.


Asunto(s)
Productos Finales de Glicación Avanzada/farmacología , NADPH Oxidasas/metabolismo , Neuronas/efectos de los fármacos , Neuronas/enzimología , Proteína Quinasa C-delta/metabolismo , Análisis de Varianza , Muerte Celular/efectos de los fármacos , Diferenciación Celular/efectos de los fármacos , Línea Celular Tumoral , Relación Dosis-Respuesta a Droga , Interacciones Farmacológicas , Humanos , Proteínas Asociadas a Microtúbulos/metabolismo , Proteínas Quinasas Activadas por Mitógenos/metabolismo , Neuroblastoma/patología , ARN Mensajero/metabolismo , Receptor para Productos Finales de Glicación Avanzada/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Tretinoina/farmacología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA